Breaking News Instant updates and real-time market news.

CGC

Canopy Growth

$49.75

2.6 (5.51%)

, APHQF

Use APHA

$0.00

(0.00%)

11:47
10/12/18
10/12
11:47
10/12/18
11:47

Canadian analyst rolls out cannabis stock coverage with four Sell ratings

Cannabis stocks are in focus after an analyst started coverage of the Canadian Cannabis sector with four Sell ratings on stocks. SELL: Veritas analyst Stuart Rolfe began coverage of the sector with four Sell ratings on Canopy Growth Corporation (CGC), Aphria (APHQF), Aurora Cannabis (ACBFF) and Cronos Group (CRON) in a note entitled "End of the Rainbow." The analyst noted that investors have already driven stock valuations for the eighth largest publicly traded Canadian cannabis producers to a combined market cap of $55B on trailing twelve month sales of $250M while "oversupply risks are rampant." Even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued," Rolfe said. CANOPY GROWTH: Rolfe, who sees an intrinsic value of C$30 for Canopy Growth shares, said the company may be at risk of too much exposure to positive projections. The analyst said Canopy appears to have the most to lose if market conditions disappoint as it bet heavily on brand power and novel formulations. He noted that while the company has rushed to ensure plenty of supply on hand, its "zealousness" could spark fierce competition with rivals, especially if demand remains low due to continued strength in black market sales. Rolfe said Canopy is "well positioned" to scale and should get product to customers effectively, however he thinks the company's branding efforts could draw negative attention from regulators. He also added that Canopy's cost disclosures are among the "least compelling and perhaps the least consistent." APHRIA: Rolfe called Aphria a "star unicorn" among the group, saying that despite the negative optics on the Nuuvera purchase, the company has been a leader in useful disclosure on strategies and operations. The analyst said the company's focus on cost management, cash flow generation and accounting detail bodes well for future performance. He believes Aphria's claim to being lowest-cost cannabis production is credible and notes the company's traditional greenhouse and pharmaceutical expertise. Rolfe said Aphria is "best positioned" to become a takeout candidate if industry consolidation continues. He sees an intrinsic value of C$19 for Aphria shares. AURORA: Rolfe said Aurora has acquired its way to becoming one of the largest scale bets on cannabis capacity available to public investors, but the company's approach seems to be "a touch unfocused". However, Aurora's loss of momentum has corrected its valuation significantly and if prospects improve, it may offer a better entry point, the analyst contended. Rolfe added that the capacity Aurora has built through acquisition is "remarkable" and could be a potential threat to competitors. The analyst also notes that Aurora's SG&A costs are "very elevated" and present "significant opacity" for investors, but he expects scale to bring relatively high SG&A down. He sees an intrinsic value of C$13 for Aurora shares. CRONOS: Rolfe, who sees an intrinsic value of C$4.50 for Cronos shares, said the company's positioning risks becoming "stale" as an undifferentiated grower with a few "solid" cannabis-related investments. He noted some of the investments may be plateauing, rather than adding growth and that without an "ahead-of-the-game" strategy for capital deployment, he sees few upside catalysts. The analyst said he views the company's current capabilities as "overvalued," but its relatively small footprint could turn the most by building out its medicinal and international channels. CANNABIS STOCKS: Other publicly traded companies in the space include CV Sciences (CVSI), India Globalization Capital (IGC) and Tilray (TLRY). PRICE ACTION: In late morning trading, Canopy Growth was up nearly 5% to $49.39, Aphria rose about 1% to $15.24, Aurora Cannabis was up 6.2% to $10.32 and Cronos Group rose 7.3% to $9.71.

CGC

Canopy Growth

$49.75

2.6 (5.51%)

APHQF

Use APHA

$0.00

(0.00%)

ACBFF

Now symbol ACB

$0.00

(0.00%)

CRON

Cronos Group

$9.80

0.76 (8.41%)

CVSI

CV Sciences

$0.00

(0.00%)

IGC

India Globalization Capital

$4.96

0.505 (11.34%)

TLRY

Tilray

$145.60

14.08 (10.71%)

  • 13

    Oct

  • 29

    Nov

CGC Canopy Growth
$49.75

2.6 (5.51%)

10/05/18
MSCO
10/05/18
NO CHANGE
Target $255
MSCO
Overweight
Constellation Brands price target raised to $255 from $251 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian believes Constellation Brands' (STZ) strong beer fundamentals in Q2 should blunt some investor concerns and continues to think that the market is not appropriately valuing the company's strong long-term growth prospects in beer. The analyst, who also views negative sentiment around the company's investment in cannabis company Canopy Growth (CGC) as overblown, keeps an Overweight rating on Constellation and raised his price target to $255 from $251.
10/09/18
COWN
10/09/18
NO CHANGE
Target $172
COWN
Outperform
Tilray price target raised to $172 from $62 at Cowen
Cowen analyst Vivien Azer raised her price target for Tilray (TLRY) to $172 from $62 and keeps an Outperform rating on the shares. The analyst also raised her price target for Outperform-rated Canopy Growth (CGC) to C$82 from C$74.
10/12/18
VERI
10/12/18
INITIATION
VERI
Sell
Canopy Growth initiated with a Sell at Veritas
Veritas analyst Stuart Rolfe started coverage of the Canadian Cannabis sector with four Sell ratings, including a Sell on Canopy Growth, in a note entitled "End of the Rainbow." The analyst, who sees an intrinsic value of C$30 for Canopy Growth shares, notes that investors have already driven stock valuations for the eight largest publicly traded Canadian cannabis producers to a combined market cap of $55B on trailing twelve month sales of $250M while "oversupply risks are rampant." Even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued," Rolfe concludes.
10/05/18
PIVT
10/05/18
NO CHANGE
Target $300
PIVT
Buy
Constellation Brands price target raised to $300 from $265 at Pivotal Research
Pivotal Research analyst Timothy Ramsey said Constellation Brands reported a "beautiful quarter" and that its core business is "growing faster than anyone believed." In terms of its investment in Canopy Growth (CGC), Ramsey said that is "very likely a masterstroke." He raised his estimates for Constellation on the heels of the report, increased his price target to $300 and keeps a Buy rating on the shares.
APHQF Use APHA
$0.00

(0.00%)

10/12/18
VERI
10/12/18
INITIATION
VERI
Sell
Aphria initiated with a Sell at Veritas
Veritas analyst Stuart Rolfe started coverage of the Canadian Cannabis sector with four Sell ratings, including a Sell on Aphria, in a note entitled "End of the Rainbow." The analyst, who sees an intrinsic value of C$19 for Aphria shares, said that even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued."
ACBFF Now symbol ACB
$0.00

(0.00%)

09/20/18
STFL
09/20/18
NO CHANGE
STFL
Top 22 Canadian cannabis stocks up 127% since Constellation pact, says Stifel
Yesterday's significant outperformance for Canadian cannabis stocks, led by Tilray (TLRY), at one point pushed the total market capitalization for Canadian Licensed Producers above $C80B, before they closed with a combined market cap of C$73B, calculates Stifel analyst Christopher Growe. Since August 15, when Constellation Brands (STZ) announced a pact to invest C$5B into Canopy Growth (CGC), the top 22 Canadian cannabis stocks are up 127% in stock price, noted Growe. A $C73B market cap in relation to what he estimates to be an addressable Canadian market of C$10B is "difficult to fathom," so valuations require global opportunities to be realized, added Growe, who said he questions the pace of development and degree of advantage for these companies. Companies in the cannabis space that can be traded in the U.S. include Aurora Cannabis (ACBFF), CV Sciences (CVSI), Canopy Growth, Cronos Group (CRON) and Tilray.
10/12/18
VERI
10/12/18
INITIATION
VERI
Sell
Aurora Cannabis initiated with a Sell at Veritas
Veritas analyst Stuart Rolfe started coverage of the Canadian Cannabis sector with four Sell ratings, including a Sell on Aurora Cannabis, in a note entitled "End of the Rainbow." The analyst, who sees an intrinsic value of C$13 for Aurora shares, said that even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued."
CRON Cronos Group
$9.80

0.76 (8.41%)

08/15/18
ADAM
08/15/18
UPGRADE
ADAM
Hold
Cronos Group upgraded to Hold from Sell at Canaccord
10/12/18
VERI
10/12/18
INITIATION
VERI
Sell
Cronos Group initiated with a Sell at Veritas
Veritas analyst Stuart Rolfe started coverage of the Canadian Cannabis sector with four Sell ratings, including a Sell on Cronos Group, in a note entitled "End of the Rainbow." The analyst, who sees an intrinsic value of C$4.50 for Cronos shares, said that even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued."
08/15/18
08/15/18
UPGRADE

Hold
Cronos Group upgraded to Hold on 'compelling' new initiatives at Canaccord
As previously reported, Canaccord analyst Matt Bottomley upgraded Cronos Group to Hold from Sell as he believe Cronos has added a number of "compelling" strategic initiatives, such as a supply agreement into Poland's recently legalized medical market; a partnership with MedMen in Canada; the creation of Cronos GrowCo; and the take-or-pay supply agreement with Cura Select of the U.S. Updating for these initiatives lead Bottomley to raise his price target on Cronos shares to C$7.50 from C$6.50.
CVSI CV Sciences
$0.00

(0.00%)

IGC India Globalization Capital
$4.96

0.505 (11.34%)

TLRY Tilray
$145.60

14.08 (10.71%)

09/06/18
09/06/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ANALYSTS WEIGH IN ON MICRON: Despite recent softness in DRAM spot pricing, the more appropriate metric for Micron Technology (MU) investors to focus on is gross margin, Deutsche Bank analyst Sidney Ho said. On gross margin, the analyst sees Micron benefiting from "solid cost improvement through technology transition" in fiscal 2019. Further, he believes the DRAM market has become more diverse, which should help offset temporary weakness in any given end market. As the company continues to execute on its technology roadmap and delivers solid operating results, Ho expects Micron's stock valuation to re-rate. He kept a Buy rating and $80 price target on Micron. However, Baird analyst Tristan Gerra said Micron is no longer a top large-cap idea, citing its valuation and the likelihood gross margins may be nearing their peak. He also noted DRAM pricing is likely peaking and NAND is in significant oversupply. Gerra maintained an Outperform rating but lowered his price target to $75 from $100 on Micron shares. ARGUS UPGRADES PG&E TO BUY: Argus analyst Jacob Kilstein upgraded PG&E (PCG) to Buy from Hold with a price target of $54, saying the company's recent California legislative victory will reduce its liability for last year's wildfire as its earnings outlook improves. Kilstein further anticipates PG&E to announce a timeline regarding its dividend reinstatement after being forced to suspend its quarterly payout on concerns about its potential wildfire damage responsibility estimated as high as $12B. NORTHLAND DOWNGRADES TILRAY TO MARKET PERFORM: Northland analyst Mike Grondahl downgraded Tilray (TLRY) to Market Perform from Outperform. While he continues to see the company playing a "huge role" in the recreational-use cannabis market in Canada and other countries and the medical market in Europe, he also believes the risk/reward is far more balanced following the recent "massive" move in the stock. JPMORGAN CUTS FRANKLIN RESOURCES TO UNDERWEIGHT: JPMorgan analyst Kenneth Worthington downgraded Franklin Resources (BEN) to Underweight from Neutral and lowered his price target for the shares to $29 from $32. The analyst believes the more recent weakness in emerging markets, and in particular in emerging market debt, will weigh on both Franklin's organic growth and earnings potential. He thinks challenges in emerging markets put additional pressure on "an already challenging growth story characterized by weak fund performance, significant outflows, and declining margins." Worthington continues to have a negative view on the asset management sector.
10/02/18
ROTH
10/02/18
NO CHANGE
ROTH
Neutral
Tilray price target removed on 'unprecedented volatility' at Roth Capital
Roth Capital analyst Scott Fortune removed Tilray's price target after assuming coverage of the stock, citing "unprecedented volatility." The analyst notes that Tilray has experienced extreme volatile trading, with the stock halted five times on September 19 and a 150-point trading swing on the same day. The stock has a small number of shares outstanding, significant short interest, and not many investors that can loan the stock to short sellers, he points out, adding that the cannabis industry continues to trade with extreme volatility due to M&A and partnership speculation. He reiterates a Neutral rating on the stock.

TODAY'S FREE FLY STORIES

KLAC

KLA-Tencor

$114.50

1.55 (1.37%)

, LRCX

Lam Research

$179.00

0.17 (0.10%)

12:11
02/23/19
02/23
12:11
02/23/19
12:11
Periodicals
Cold War in tech should not be ignored, Barron's says »

While investors are…

KLAC

KLA-Tencor

$114.50

1.55 (1.37%)

LRCX

Lam Research

$179.00

0.17 (0.10%)

ADI

Analog Devices

$105.90

0.64 (0.61%)

NVDA

Nvidia

$159.45

3.69 (2.37%)

SWKS

Skyworks

$82.43

0.67 (0.82%)

XLNX

Xilinx

$122.97

3.77 (3.16%)

INTC

Intel

$52.58

1.18 (2.30%)

AMAT

Applied Materials

$39.40

0.56 (1.44%)

MXIM

Maxim Integrated

$55.88

0.65 (1.18%)

AMD

AMD

$24.40

0.48 (2.01%)

NXPI

NXP Semiconductors

$94.49

0.09 (0.10%)

AVGO

Broadcom

$276.39

-4.42 (-1.57%)

MRVL

Marvell

$19.65

0.05 (0.26%)

MU

Micron

$42.53

1.01 (2.43%)

QCOM

Qualcomm

$53.12

0.77 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 12

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 20

    Mar

  • 25

    Mar

  • 26

    Mar

  • 09

    Apr

  • 28

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

09:25
02/23/19
02/23
09:25
02/23/19
09:25
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

, XRX

Xerox

$31.50

0.16 (0.51%)

08:29
02/23/19
02/23
08:29
02/23/19
08:29
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

XRX

Xerox

$31.50

0.16 (0.51%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.81

0.02 (0.14%)

F

Ford

$8.71

(0.00%)

GM

General Motors

$39.98

0.35 (0.88%)

HMC

Honda

$28.17

0.43 (1.55%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$121.84

0.66 (0.54%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$31.51

-0.62 (-1.93%)

LUV

Southwest

$53.62

-0.69 (-1.27%)

VZ

Verizon

$56.95

0.81 (1.44%)

TMUS

T-Mobile

$73.17

-0.09 (-0.12%)

T

AT&T

$31.15

0.32 (1.04%)

NOK

Nokia

$6.21

0.06 (0.98%)

ERIC

Ericsson

$9.51

0.285 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 03

    Mar

  • 04

    Mar

  • 11

    Mar

  • 13

    Mar

  • 20

    Mar

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

AIMT

Aimmune

$23.70

0.73 (3.18%)

, AZN

AstraZeneca

$40.95

0.515 (1.27%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
The American Academy of Asthma, Allergy & Immunology to hold annual meeting »

AAAAI Annual Meeting 2019…

AIMT

Aimmune

$23.70

0.73 (3.18%)

AZN

AstraZeneca

$40.95

0.515 (1.27%)

TEVA

Teva

$17.28

0.03 (0.17%)

NVS

Novartis

$90.77

0.26 (0.29%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SHPG

Shire

$0.00

(0.00%)

REGN

Regeneron

$422.43

3.77 (0.90%)

SNY

Sanofi

$41.20

-0.13 (-0.31%)

ALK

Alaska Air

$62.35

-0.48 (-0.76%)

ABT

Abbott

$76.40

1.26 (1.68%)

CVS

CVS Health

$62.00

-0.33 (-0.53%)

KALV

KalVista

$20.74

-0.04 (-0.19%)

BCRX

BioCryst

$8.99

0.32 (3.69%)

OPTN

Optinose

$7.31

0.02 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

  • 18

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.